At the annual AMP meeting this week, we announced that we’ve started to enroll more clinical labs into the Early Access Program for our new clinical interpretation and reporting solution for molecular pathologists and medical geneticists. It’s an exciting milestone for us and represents the first product in the Ingenuity portfolio that is specifically designed to address major challenges of scale, speed and decision support that healthcare laboratories face with the adoption of next generation sequencing-based applications.
This new interpretation and reporting solution draws upon the vast clinical and genomic data in the expert-curated Ingenuity Knowledge Base and provides clinical labs with automated scoring, interpretation and reporting of genetic variant findings in standardized, HIPAA Safe Harbor-compliant formats. The time required to make accurate clinical assessments of variants from next-generation sequencing data – especially as tests move from single-gene to multiple-gene to panels, exomes and whole genomes – is becoming a fundamental bottleneck and is slowing the adoption of these data in clinical applications.
Some of the “early” Early Access Program members we have already been working with include Partners Healthcare, Emory Genetics Laboratory, and GeneDx, who have all provided important input (thank you!) into the development of this exciting new solution. We will also be launching a larger beta program in early 2014; interested labs can learn more at http://www.ingenuity.com/ngs-clinical-beta. Sign up for email updates and be among the first to receive information on this powerful new clinical solution.